AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results

AstraZeneca said on September 4 that it has initiated a PI/II clinical study of its novel coronavirus vaccine AZD1222 in Japan, planning to enroll Japanese male and female subjects over 18 years of age, with a target number of around...read more